Published in Clin Exp Metastasis on January 01, 2000
Nonreceptor tyrosine kinases in prostate cancer. Neoplasia (2007) 1.50
Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev (2010) 1.29
Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol (2013) 1.13
Estrogens and prostate cancer: etiology, mediators, prevention, and management. Endocrinol Metab Clin North Am (2011) 0.88
Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells. Biochem Biophys Res Commun (2007) 0.86
Specific amino acid restriction inhibits attachment and spreading of human melanoma via modulation of the integrin/focal adhesion kinase pathway and actin cytoskeleton remodeling. Clin Exp Metastasis (2004) 0.86
Perspectives on the role of isoflavones in prostate cancer. AAPS J (2013) 0.82
Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells. J Cell Physiol (2008) 0.82
The role of integrin-β/FAK in cyclic mechanical stimulation in MG-63 cells. Int J Clin Exp Pathol (2014) 0.77
Soy isoflavones and cellular mechanics. J Bioenerg Biomembr (2013) 0.76
Integrins: versatility, modulation, and signaling in cell adhesion. Cell (1992) 34.06
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A (1992) 8.46
Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature (1995) 8.25
Signal transduction from the extracellular matrix. J Cell Biol (1993) 7.64
Adhesion of cells to surfaces coated with polylysine. Applications to electron microscopy. J Cell Biol (1975) 5.78
Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature (1992) 5.72
Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A (1992) 5.06
Tensegrity: the architectural basis of cellular mechanotransduction. Annu Rev Physiol (1997) 5.02
Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem (1992) 4.33
Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK. Mol Cell Biol (1994) 4.11
Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell (1996) 3.60
Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell (1992) 2.92
Signaling through focal adhesion kinase. Bioessays (1997) 2.77
Autonomous expression of a noncatalytic domain of the focal adhesion-associated protein tyrosine kinase pp125FAK. Mol Cell Biol (1993) 2.75
Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas. Proc Natl Acad Sci U S A (1995) 2.67
Paxillin, a tyrosine phosphorylated focal adhesion-associated protein binds to the carboxyl terminal domain of focal adhesion kinase. Mol Biol Cell (1995) 2.57
An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase. Mol Cell Biol (1996) 2.38
A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res (1989) 2.18
Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ (1996) 2.09
A transmembrane-anchored chimeric focal adhesion kinase is constitutively activated and phosphorylated at tyrosine residues identical to pp125FAK. J Biol Chem (1994) 1.83
Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer (1996) 1.79
Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl (1990) 1.75
Progressive loss of shape-responsive metabolic controls in cells with increasingly transformed phenotype. Cell (1981) 1.59
Integrin signaling. Matrix Biol (1997) 1.14
Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl (1994) 1.12
Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res (1997) 1.10
Enhancement of experimental colon cancer by genistein. Cancer Res (1997) 1.07
pp125FAK tyrosine kinase activity is not required for the assembly of F-actin stress fibres and focal adhesions in cultured mouse aortic smooth muscle cells. J Cell Sci (1995) 1.07
Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol (1997) 1.04
Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin. Clin Exp Metastasis (1996) 1.01
Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res (1993) 0.94
Tumour suppressor genes in prostate cancer. Semin Cancer Biol (1997) 0.92
Cancer chemoprevention agent development strategies for genistein. J Nutr (1995) 0.91
Prostate cancer--biology of metastasis and its clinical implications. World J Urol (1996) 0.90
Differences in the biosynthesis and localization of the fibronectin receptor in normal and transformed cultured human cells. Cancer Res (1990) 0.88
Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res (1994) 0.85
Stimulation of tyrosine- and serine-phosphorylation of focal adhesion kinase in mouse 3T3 cells by fibronectin and fibroblast growth factor. FEBS Lett (1994) 0.82
Correlations between the expression, phosphotyrosine content and enzymatic activity of focal adhesion kinase, pp125FAK, in tumor and nontransformed cells. Cancer Biochem Biophys (1996) 0.80
Common individual antigenic determinants in five of eight BALB-c IgA myeloma proteins that bind phosphoryl choline. J Exp Med (1970) 4.49
Genetics of a new IgVH (T15 idiotype) marker in the mouse regulating natural antibody to phosphorylcholine. J Exp Med (1974) 3.64
Genetics of immunoglobulins in the mouse. Adv Immunol (1967) 3.14
H-2-linked immune response (Ir) genes. Independent loci for Ir-IgG and Ir-IgA genes. J Exp Med (1972) 2.50
A mouse IgM allotypic determinant (Igh-6.5) recognized by a monoclonal rat antibody. J Immunol (1981) 2.27
Inability of mice with a defect in B-lymphocyte maturation to respond to phosphorycholine on immunogenic carriers. J Exp Med (1977) 2.18
Association of H-2 types with genetic control of immune responsiveness to IgA allotypes in the mouse. Proc Natl Acad Sci U S A (1971) 2.07
Choroid plexus cysts: not associated with Down syndrome. Ultrasound Obstet Gynecol (1996) 2.02
Clonal nature of the immune response to phosphorylcholine. II. Idiotypic specificity and binding characteristics of anti-phosphorylcholine antibodies. J Immunol (1974) 1.95
Multiple individual and cross-specific indiotypes on 13 levan-binding myeloma proteins of BALB/c mice. J Exp Med (1975) 1.94
Serum concentrations and allotypes of immunoglobulins in two lines of mice genetically selected for "high" or "low" antibody synthesis. J Exp Med (1970) 1.93
Attachment security in infancy and early adulthood: a twenty-year longitudinal study. Child Dev (2000) 1.92
The development of a risk-adjusted capitation payment system: the Maryland Medicaid model. J Ambul Care Manage (1998) 1.86
Clonal nature of the immune response to phosphorylcholine. I. Specificity, class, and idiotype of phosphorylcholine-binding receptors on lymphoid cells. J Exp Med (1974) 1.85
Venous pH can safely replace arterial pH in the initial evaluation of patients in the emergency department. Emerg Med J (2001) 1.80
Structure of human skeletal keratosulfate. The linkage region. J Biol Chem (1967) 1.77
Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A (2005) 1.74
Association of H-2 types with genetic control of immune reponsiveness to IgG (gamma2a) allotypes in the mouse. J Exp Med (1972) 1.71
Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr (2000) 1.69
Genetics of mouse antibodies. I. Linkage of the dextran response locus, VH-DEX, to allotype. Eur J Immunol (1975) 1.68
Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis. Brain Dev (1994) 1.63
Idiotype of inulin-binding antibodies and myeloma proteins controlled by genes linked to the allotype locus of the mouse. J Immunol (1976) 1.62
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med (1995) 1.60
MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene (2006) 1.60
Immune response to levan. I. Kinetics and ontogeny of anti-levan and anti-inulin antibody response and of expression of cross-reactive idiotype. J Immunol (1978) 1.57
Crossing over between genes in the immunoglobulin heavy chain linkage group of the mouse. J Exp Med (1969) 1.56
Mechanism of antidiuretic effect of beta adrenergic stimulation. J Clin Invest (1972) 1.54
Lyb-7, a new B cell alloantigen controlled by genes linked to the IgCH locus. J Immunol (1979) 1.43
Bayesian monitoring of phase II trials in cancer chemoprevention. J Clin Epidemiol (1999) 1.41
Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst (1997) 1.40
Immune response to levan. III. The capacity to produce anti-inulin antibodies and cross-reactive idiotypes appears late in ontogeny. J Immunol (1979) 1.34
Receptors for immunoglobulin and complement on mouse leukemias and lymphomas. J Immunol (1972) 1.31
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
Genetic factors controlling anti-sheep erythrocyte antibody response and immunoglobulin synthesis in backcross and F2 progeny of mice genetically selected for "high" or "low" antibody synthesis. J Exp Med (1972) 1.26
Alcoholics admitted to four hospitals in England. II. General and cause-specific mortality. Q J Stud Alcohol (1974) 1.23
Close linkage in genes controlling gamma-A and gamma-G heavy chain structure in BALB/c mice. J Mol Biol (1966) 1.22
High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. Anal Biochem (2001) 1.20
Alcoholics admitted to four hospitals in England. I. Social class and the interaction of alcoholics with the treatment system. Q J Stud Alcohol (1974) 1.18
Regulation of the anti-inulin antibody response by a nonallotype-linked gene. J Exp Med (1980) 1.14
Isoantibodies specific for myeloma gamma-G and gamma-H immunoglobulins of BALB-c mice. J Mol Biol (1966) 1.13
Genetic and cellular regulation of the expression of specific antibody idiotypes in the anti-polyfructosan immune response. Ann Immunol (Paris) (1979) 1.10
An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. J Clin Pharmacol (1993) 1.09
Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene (2007) 1.08
2-chain immunoglobulin A molecules: abnormal or normal intermediates in synthesis. Science (1968) 1.06
Early stages of p53-induced apoptosis are reversible. Cell Death Differ (2001) 1.05
Chemoprevention of prostate cancer: concepts and strategies. Eur Urol (1999) 1.04
Pseudoaneurysm of the external carotid artery following radical neck dissection and irradiation: a case report and review of the literature. Cardiovasc Surg (1994) 1.02
Immune response to levan. II. T independence of suppression of cross-reactive idiotypes by anti-idiotype antibodies. J Immunol (1979) 1.02
Induction of major histocompatibility class I antigens by interferons in undifferentiated F9 cells. J Cell Physiol (1987) 1.01
Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin. Clin Exp Metastasis (1996) 1.01
Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification. Prostate Cancer Prostatic Dis (2006) 1.00
Levamisole-mediated restoration of cellular immunity in peripheral blood lymphocytes of patients with immunodeficiency diseases. Clin Immunol Immunopathol (1976) 0.99
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori (1998) 0.99
Direct and indirect suppression induced by anti-idiotype antibody in the inulin-bacterial levan antigenic system. Mol Immunol (1979) 0.98
Computer-assisted image analysis-derived intermediate endpoints. Urology (2001) 0.96
Preparation of functionalized derivatives of inulin: conjugation of erythrocytes for hemagglutination and plaque-forming cell assays. J Immunol Methods (1979) 0.96
Progress in cancer chemoprevention. Ann N Y Acad Sci (1999) 0.95
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer (1995) 0.95
Alcoholism and correlates of mortality. Implications for epidemiology. J Stud Alcohol (1978) 0.94
Polymorphism of heavy-chain genes in immunoglobulins of wild mice. Science (1966) 0.93
Development of chemopreventive agents for lung and upper aerodigestive tract cancers. J Cell Biochem Suppl (1993) 0.93
Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol (1999) 0.92
Medical consequences of the New Mexico State Penitentiary riot. Ann Emerg Med (1983) 0.91
Effect of progesterone and 17 beta-estradiol on the production of uteroglobin by cultured rabbit uterine epithelial cells. Endocrinology (1983) 0.91
Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast. J Pathol (2009) 0.91
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol (1996) 0.91
How accurate are pulse oximeters in patients with acute exacerbations of chronic obstructive airways disease? Respir Med (2001) 0.90
Idiotypes of inulin-binding myeloma proteins localized to variable region light and heavy chains: genetic significance. J Exp Med (1977) 0.89
The immune response to the alpha 1-6 epitope of dextran is determined by a gene linked to the IgCH locus. Scand J Immunol (1979) 0.89
Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia (1999) 0.89
Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate (1998) 0.89
Sleep habits in toddlers 18 to 36 months old. J Am Acad Child Adolesc Psychiatry (1987) 0.88
Cytogenetic engineering in vivo: restoration of biologic complement activity to C5-deficient mice by intravenous inoculation of hybrid cells. Proc Natl Acad Sci U S A (1973) 0.88
Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res Dev (1995) 0.88
Ontogeny of B lymphocytes. 3. H-2 linkage of a gene controlling the rate of appearance of complement receptor lymphocytes. J Exp Med (1974) 0.87
Effect of over-expression of bacterial ribonuclease H on the utility of antisense MYC oligodeoxynucleotides in the monocytic leukemia cell line U937. Biochimie (1993) 0.87
DNA repair is activated in early stages of p53-induced apoptosis. Cell Death Differ (2000) 0.87
Effect of plasma albumin on sodium reabsorption in patients with nephrotic syndrome. Kidney Int (1972) 0.87
How much observational data is enough? An empirical test using marital interaction coding. Behav Ther (2001) 0.87
Estrogen and progesterone regulation of proliferation and differentiation of rabbit uterine epithelium. Prog Clin Biol Res (1984) 0.87
Pharmacokinetics of amifostine: effects of dose and method of administration. Semin Oncol (1999) 0.86
Allelic forms of anti-phosphorylcholine antibodies. J Immunol (1981) 0.86
Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev (1998) 0.85
Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res (1994) 0.85
Genetic control of antibody responses to myeloma proteins of mice. Contemp Top Immunobiol (1974) 0.85
The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma. Cancer (1975) 0.84
Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology (2001) 0.83
Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer (1994) 0.83
Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood (1996) 0.83
Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit (1995) 0.83
Induction of cell-mediated immunity against leukemia EL4 in C57BL mice. J Natl Cancer Inst (1973) 0.83
Immunochemical and genetic studies of two distinct gamma-G-immunoglobulins in BALB-c mice. J Immunol (1965) 0.83
Development and certification of green tea-containing standard reference materials. Anal Bioanal Chem (2011) 0.83
T15 D region germ line amino acid sequences distinguished by monoclonal anti-idiotope antibody. J Immunol (1985) 0.83
Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer Prostatic Dis (2001) 0.83